1. Slide Source: Lipids Online Slide Library www.lipidsonline.org ASTEROID Population at Baseline (n=507) Patients Completing (n=349) Patients Not Completing (n=158) Age, years (mean)58.5 Male70.2%72.8% Weight, kg (mean)85.586.2 Body mass index (median)28.428.9 History of hypertension96.0%93.7% History of diabetes mellitus13.2%11.4% Concomitant Medications Aspirin83.7%83.5% ACE inhibitors53.3%45.6% Angiotensin receptor antagonists 18.3%13.3% Organic nitrates85.1%87.3% Beta-blockers84.2%73.4% Nissen SE et al. JAMA 2006;295:1556-1565.

2. Slide Source: Lipids Online Slide Library www.lipidsonline.org Lipid Values and Percent Change (n=346) Mean Baseline Mean during Treatment Percent Change p Value Total cholesterol (mg/dL) 204.0133.8–33.8<0.001 LDL-C (mg/dL) 130.460.8–53.2<0.001 HDL-C (mg/dL) 43.149.0+14.7<0.001 Triglycerides (mg/dL) 152.2121.2–14.5<0.001 LDL-C/HDL-C ratio3.21.3–58.5<0.001 Nissen SE et al. JAMA 2006;295:1556-1565.

3. Slide Source: Lipids Online Slide Library www.lipidsonline.org Dual Primary IVUS Efficacy Parameters Regression p<0.001* –0.79 *Wilcoxon signed rank test for comparison with baseline Change in Percent Atheroma Volume (%) Change in Percent Atheroma Volume (mm 3 ) –5.6 Regression p<0.001* Nissen SE et al. JAMA 2006;295:1556-1565. Median Change in Percent Atheroma Volume Median Change in Most Diseased Subsegment

4. Slide Source: Lipids Online Slide Library www.lipidsonline.org Recent Coronary IVUS Progression Trials Relationship Between LDL-C and Progression Rate Median Change in Percent Atheroma Volume (%) 5060708090100110120 Mean LDL-C (mg/dL) ASTEROID rosuvastatin R 2 = 0.95 p<0.001 CAMELOT placebo REVERSAL pravastatin ACTIVATE placebo A-Plus placebo REVERSAL atorvastatin Nissen SE et al. JAMA 2006;295:1556-1565.